Skip to content

Trial Summary

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

Acronym:

RELATIVITY098

ACTRN/NCT /ethics:

NCT05002569

Scientific title:

A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Sponsor / Cooperative group:

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2021-10-19
Anticipated End Date2025-12-15

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting